Antibody-drug conjugates (ADCs) represent the next frontier in targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. One of the most critical components in constructing effective ADCs is the linker technology, which bridges the antibody and the cytotoxin. A deep dive into ADC linkers reveals the complexities behind developing ADC linkers and their conjugation with cytotoxins, leading to promising advancements in oncology.